"The Trump administration’s unilateral and misguided decision to slash and cap the indirect cost rate for research funded by the National Institutes of Health sabotages the decades-long partnership that has ensured U.S. global leadership in life-saving medical research. This partnership has sparked innovations that have strengthened the U.S. economy, created good-paying jobs, and helped to educate generations of researchers and scientists.
Support for the research enterprise allows colleges and universities to maintain the cutting-edge laboratories and advanced technologies needed to stay ahead of foreign competitors and deliver pioneering discoveries that benefit the health and well-being of all Americans.
This decision is short-sighted, naive, and dangerous. It will be celebrated wildly by our competitors, who will see this for what it is—a surrender of U.S. supremacy in medical research. It is a self-inflicted wound that, if not reversed, will have dire consequences on U.S. jobs, global competitiveness, and the future growth of a skilled workforce."